In this free webinar, learn how neuroscience sponsors are rethinking patient identification, endpoint selection and treatment-response assessment across complex CNS disorders. The featured speakers will discuss examples from neurodegenerative disease, psychiatry and psychedelic medicine, along with how these factors influence trial design and execution. Attendees will also explore the scientific, operational and regulatory trends expected to shape neuroscience development over the next five years.
, /PRNewswire/ — Neuroscience clinical development is evolving across Alzheimer’s disease, Parkinson’s disease, psychiatry and other complex CNS disorders. Disease heterogeneity, trial accessibility, endpoint selection and variability in treatment response are challenging traditional approaches to how sponsors identify patients, measure treatment effects and make development decisions.
This webinar will explore how sponsors are addressing these challenges across neuroscience. Panelists will examine approaches to patient identification and enrollment, why traditional measures of treatment response are being re-examined and how sponsors are evaluating endpoints that better capture clinically meaningful change.
Examples from neurodegenerative disease, psychiatry and emerging fields such as psychedelic medicine will illustrate how patient populations, endpoints and measures of treatment response are influencing trial design and execution. The discussion will also look ahead at the scientific, operational and regulatory trends likely to shape neuroscience development over the next five years.
Attendees will gain practical insights into how sponsors are adapting development strategies across CNS disorders, from identifying appropriate patient populations and selecting meaningful endpoints to navigating evolving trial requirements and applying study data to development decisions.
Register for this webinar to learn how evolving approaches to neuroscience clinical development can inform patient identification, endpoint selection and future clinical trial strategies.
Join experts from Syneos Health, Jason Tibbs (Moderator), Global Therapeutic Head, Neuroscience & Ophthalmology; Alexandria Wise, Head of R&D and Scientific Strategy; and Zia Choudhry, Head of R&D and Scientific Strategy, for the live webinar on Tuesday, December 1, 2026, at 11am EST (5pm CET / EU-Central).
For more information, or to register for this event, visit Neuroscience Development: Are We Measuring What Matters?.
ABOUT XTALKS
Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.
Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.
To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/
Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]
SOURCE Xtalks
